Search results for: tumor
#32272509 2020/04/10 To Up
Dexamethasone Interferes with Autophagy and Affects Cell Survival in Irradiated Malignant Glioma Cells.Radiation is known to induce autophagy in malignant glioma cells whether it is cytocidal or cytoprotective. Dexamethasone is frequently used to reduce tumor-associated brain edema, especially during radiation therapy. The purpose of the study was to determine whether and how dexamethasone affects autophagy in irradiated malignant glioma cells and to identify possible intervening molecular pathways.
Alfred Komakech, Ji-Hye Im, Ho-Shin Gwak, Kyue-Yim Lee, Jong Heon Kim, Byong Chul Yoo, Heesun Cheong, Jong Bae Park, Ji Woong Kwon, Sang Hoon Shin, Heon Yoo
1888 related Products with: Dexamethasone Interferes with Autophagy and Affects Cell Survival in Irradiated Malignant Glioma Cells.1.00 flask-100 µg1x10e7 cells96 tests1.00 flask100 µg1x10e7 cells96 tests1.00 flask
#32272502 2020/04/09 To Up
The interplay between innate and adaptive immunity in cancer shapes the productivity of cancer immunosurveillance.The immune system is a vital determinant of cancer and shapes its trajectory. Notably, the immune reaction to cancer harbors dual potential for suppressing or promoting cancer development and progression. This polarity of the immune response is determined, in part, by the character of the interplay between innate and adaptive immunity. On the one hand, the innate immune compartment is a necessary proponent of cancer immunity by supporting an immunostimulatory state that enables T cell immunosurveillance. However, in the setting of cancer, innate immune cells are commonly polarized with immune-suppressive properties and as a result, orchestrate a tolerogenic niche that interferes with the cytotoxic potential of tumor antigen-specific T cells. Here, we discuss the role of innate immunity as a positive and negative regulator of adaptive immunosurveillance; moreover, we highlight how tumor cells may skew leukocytes toward an immunosuppressive state and, as such, subvert the phenotypic plasticity of the immune compartment to advance disease progression. These observations establish the precedent for novel therapeutic strategies that aim to restore the tumor microenvironment to an immunoreactive state and, in doing so, condition and maintain the immunogenicity of tumors to yield deep and durable responses to immunotherapy.
Renee B Chang, Gregory L Beatty
2000 related Products with: The interplay between innate and adaptive immunity in cancer shapes the productivity of cancer immunosurveillance.
#32272498 2020/04/09 To Up
NFE2L2/KEAP1 mutations correlate with higher TMB value/PD-L1 expression and potentiate improved clinical outcome with immunotherapy.Abnormalities in the KEPA1-NRF2 pathway have a role in cancer progression, metastasis, and resistance to chemo-/radio-therapies. Persistent activation of NRF2 associates with poor prognosis across different cancer types. However, the beneficial therapeutic strategy to harness this pathway in cancer remains unclear. This study aimed to investigate the clinical outcome with immunotherapy in NFE2L2/KEAP1 mutant population.
Xian Xu, Yang Yang, Xiaoyan Liu, Na Cao, Peng Zhang, Songhui Zhao, Donglin Chen, Li Li, Yong He, Xiaowei Dong, Kai Wang, Hanqing Lin, Naiquan Mao, Lingxiang Liu
1644 related Products with: NFE2L2/KEAP1 mutations correlate with higher TMB value/PD-L1 expression and potentiate improved clinical outcome with immunotherapy.0.1 mg500 mg
#32272497 2020/04/09 To Up
Unravelling the heterogeneity and dynamic relationships of tumor-infiltrating T cells by single-cell RNA sequencing analysis.T cells are crucial for the success of immune-based cancer therapy. Reinvigorating antitumor T cell activity by blocking checkpoint inhibitory receptors has provided clinical benefits for many cancer patients. However, the efficacy of these treatments varies in cancer patients and the mechanisms underlying these diverse responses remain elusive. The density and status of tumor-infiltrating T cells have been shown to positively correlate with patient response to checkpoint blockades. Therefore, further understanding of the heterogeneity, clonal expansion, migration, and effector functions of tumor-infiltrating T cells will provide fundamental insights into antitumor immune responses. To this end, recent advances in single-cell RNA sequencing technology have enabled profound and extensive characterization of intratumoral immune cells and have improved our understanding of their dynamic relationships. Here, we summarize recent progress in single-cell RNA sequencing technology and current strategies to uncover heterogeneous tumor-infiltrating T cell subsets. In particular, we discuss how the coupling of deep transcriptome information with T cell receptor (TCR)-based lineage tracing has furthered our understanding of intratumoral T cell populations. We also discuss the functional implications of various T cell subsets in tumors and highlight the identification of novel T cell markers with therapeutic or prognostic potential.
Xin Yu, Lei Zhang, Ashutosh Chaudhry, Aaron S Rapaport, Wenjun Ouyang
1508 related Products with: Unravelling the heterogeneity and dynamic relationships of tumor-infiltrating T cells by single-cell RNA sequencing analysis.100.00 ug1.00 flask100 extractions96 tests25 TESTS
#32272491 2020/04/09 To Up
The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities.Early-phase clinical trials using oral inhibitors of MEK, the mitogen-activated protein kinase kinase, have demonstrated benefit for patients with neurofibromatosis type 1 (NF1)-associated tumors, particularly progressive low-grade gliomas and plexiform neurofibromas. Given this potential of MEK inhibition as an effective medical therapy, the use of targeted agents in the NF1 population is likely to increase substantially. For clinicians with limited experience prescribing MEK inhibitors, concern about managing these treatments may be a barrier to use. In this manuscript, the Clinical Care Advisory Board of the Children's Tumor Foundation reviews the published experience with MEK inhibitors in NF1 and outlines recommendations for side-effect management, as well as monitoring guidelines. These recommendations can serve as a beginning framework for NF providers seeking to provide the most effective treatments for their patients. IMPLICATIONS FOR PRACTICE: Neurofibromatosis type 1 (NF1) clinical care is on the cusp of a transformative shift. With the success of recent clinical trials using MEK inhibitors, an increasing number of NF1 patients are being treated with MEK inhibitors for both plexiform neurofibromas and low-grade gliomas. The use of MEK inhibitors is likely to increase substantially with the expected upcoming approval of selumetinib for a specific indication for treatment of plexiform neurofibromas in NF1. Given these changes, the Clinical Care Advisory Board of the Children's Tumor Foundation has identified a need within the NF1 clinical community for guidance for the safe and effective use of MEK inhibitors for NF1-related tumors. This article provides a review of the published experience of MEK inhibitors in NF1 and provides recommendations for monitoring and management of side effects.
Laura J Klesse, Justin T Jordan, Heather B Radtke, Tena Rosser, Elizabeth Schorry, Nicole Ullrich, David Viskochil, Pamela Knight, Scott R Plotkin, Kaleb Yohay
1953 related Products with: The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities.8 inhibitors 5 G10 10mg5 Inhibitors96 wells (1 kit)1 mg96T14 inhibitors1 mg
#32272477 2020/04/09 To Up
Heterogeneity Fair: Commentary to Menter and Tzankov "Lymphomas and Their Microenvironment: A Multifaceted Relationship".
2747 related Products with: Heterogeneity Fair: Commentary to Menter and Tzankov "Lymphomas and Their Microenvironment: A Multifaceted Relationship".100ug10 mg1000 tests100ul500 mg50 ug 25 mg1000 TESTS/0.65ml10 mg 5 G100ug25 mg
No related Items
#32272454 2020/04/09 To Up
Construction and evaluation of hyaluronic acid-based copolymers as a targeted chemotherapy drug carrier for cancer therapy.Melanoma (MM) is a highly aggressive skin cancer with limited treatment options. Although chemotherapy has been using for advanced melanoma treatment, the lack of targetability, the poor biocompatibility and the severe side effects still hamper the wide applications of chemotherapy agents in MM management. Herein, a biocompatible and biodegradable polymeric hyaluronic acid nanoparticle (HANP) encapsulated with Paclitaxel (PTX) was developed for MM targeted therapy. Our results showed that PTX at 37 ± 2.1% (w/w) was able to be loaded into HANP with over five days of stability under physiological conditions. In vitro, HANP/PTX presented hyaluronidase-dependent drug release. Compared to free PTX, HANP/PTX demonstrated a 6-75 times higher growth inhibition in five different cancer cells, while only presenting minimum toxicity to normal cells. After intravenous administration at a 10 mg/kg equivalent dose of PTX, HANP/PTX significantly ablated MM tumor growth in a mouse model. As confirmed by 18F-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) imaging, the tumors started to respond to the HANP/PTX as early as seven days after the initial treatment, which will significantly benefit for personalized treatment. In conclusion, the HANP/PTX nanocomplex demonstrated great promise as a translational nanomedicine for cancer chemotherapy.
Yuting Tang, Minglong Chen, Qian Xie, Lu Li, Lei Zhu, Qingjie Ma, Shi Gao
1044 related Products with: Construction and evaluation of hyaluronic acid-based copolymers as a targeted chemotherapy drug carrier for cancer therapy.1KG100 μl100 assays 1KG100tests 500 G100ug Lyophilized100 assays100ug Lyophilized96 Tests
#32272445 2020/04/01 To Up
Meta-analysis of risk factors for CCLNM in patients with unilateral cN0 PTC.Papillary thyroid cancer (PTC) patients with clinical negative central lymph nodes (cN0), the use of prophylactic central lymph node dissection remains controversial. Patients with cN0 disease receive contralateral central lymph node metastasis (CCLNM) 3.88-30.63% of cases. Therefore, the present study aimed to obtain evidence for CCLNM risk factors in unilateral cN0 PTC.
Wei Sun, Boyuan Zheng, Zhihong Wang, Wenwu Dong, Yuan Qin, Hao Zhang
1829 related Products with: Meta-analysis of risk factors for CCLNM in patients with unilateral cN0 PTC.100 G100 units250 mg 1 G 1 G 5 G500 MG1 Set
#32272431 2020/04/06 To Up
Shikonin mitigates ovariectomy-induced bone loss and RANKL-induced osteoclastogenesis via TRAF6-mediated signaling pathways.Postmenopausal osteoporosis results from estrogen withdrawal and is characterized mainly by bone resorption. Shikonin is a bioactive constitute of Chinese traditional herb which plays a role in antimicrobial and antitumor activities. The study was designed to investigate the role of shikonin on postmenopausal osteoporosis and explore its underlying mechanisms.
Kai Chen, Zijun Yan, Yiran Wang, Yilin Yang, Mengxi Cai, Chunyou Huang, Bo Li, Mingyuan Yang, Xiaoyi Zhou, Xianzhao Wei, Changwei Yang, Ziqiang Chen, Xiao Zhai, Ming Li
1042 related Products with: Shikonin mitigates ovariectomy-induced bone loss and RANKL-induced osteoclastogenesis via TRAF6-mediated signaling pathways.400 ug100ug96T400 ug100 ul 100ul96 assays1 mg100 ul2ug1 mg50 ul
Error loading info... Pleas try again later.
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
Schweiz Züri +41435006251
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
GENTAUR Nederland BV
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
53 Iskar Str. 1191 Kokalyane, Sofia